ArticleJournal of gynecologic oncology2024

Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer.

Gengwei Huo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.